文献速递头颈部肿瘤放疗放疗物理与技术

基于体素分析识别头颈癌放疗后口干的新功能亚区

Voxel-based Analysis Identifies New Functional Subregions Predictive of Xerostomia After Head and Neck Cancer Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-02-16

发现对侧腮腺和管状腺内两个亚区剂量与口干相关,预测AUC均达0.88,支持将亚区剂量指标和管状腺保护纳入放疗计划。

要点

  • 体素分析识别出对侧腮腺和管状腺内与口干相关的亚区。
  • 亚区剂量>11.5 Gy与12个月口干显著相关,预测AUC达0.88。
  • 结果提示整体腮腺剂量指标不足以预测口干,应纳入亚区剂量。

核心结论

  • 体素分析识别出对侧腮腺和管状腺内两个预测亚区,与放疗后12个月口干强相关。
  • 研究结果为腮腺保护后口干仍持续提供合理解释,支持将亚区剂量指标和管状腺保护纳入放疗计划。

研究设计与样本

  • 采用定制体素分析比较有无口干患者的体素剂量差异(标准组用计划剂量,自适应组用累积剂量),置换检验识别亚区。
  • 功能唾液腺图谱来自13例前列腺癌患者的PSMA-PET/CT扫描,用于评估亚区临床相关性。

主要发现

  • 体素分析识别出一个300.2 cc亚区,口干患者剂量显著更高,位于对侧鼻咽附近。
  • 与功能PSMA-PET图谱重叠发现对侧腮腺亚区(SRSPG,6.8 cc)和管状腺亚区(SRStubarial,12.7 cc),口干患者剂量高>11.5 Gy。
  • 逻辑回归模型预测性能高,SRSPG和SRStubarial的最大AUC均为0.88。

关键数值与推荐

  • 口干定义:治疗后12个月刺激唾液流率≤500 mg/min。
  • SRSPG和SRStubarial在口干患者中剂量高>11.5 Gy。
  • SRSPG预测口干最大AUC为0.88,SRStubarial最大AUC为0.88。

临床怎么用

  • 放疗计划可考虑纳入对侧腮腺和管状腺亚区剂量指标,以更好预测和减少口干。
  • 管状腺保护可能作为腮腺保护之外的补充策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Xerostomia is a common and debilitating toxicity following head and neck cancer radiation therapy (RT). Although adaptive RT (ART) strategies can reduce mean parotid gland (PG) dose, clinical trials have shown limited benefit in reducing xerostomia, suggesting global dose metrics may be insufficient. Voxel-based analysis (VBA) enables assessing local dose-toxicity relationships and may identify symptom-related subregions (SRS) more predictive of toxicity. This study aimed to identify xerostomia-associated SRS using VBA and assess their relevance using a functional salivary atlas. METHODS AND MATERIALS: Sixty patients with locally advanced oropharyngeal cancer treated with chemoradiation therapy were randomized to receive standard RT or weekly ART. Xerostomia was assessed at 12 months posttreatment using stimulated salivary flow, with values ≤500 mg/min indicating xerostomia. A customized VBA was applied to identify subregions from voxelwise dose differences between patients with and without xerostomia using a permutation test (planned dose in the standard arm and accumulated dose in the ART arm). To assess clinical relevance, a functional salivary atlas was generated from prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) scans of 13 patients with prostate cancer and compared with the subregions. A dosimetric analysis evaluated the predictive value of dose in overlapping regions. RESULTS: VBA identified a subregion (300.2 cc) with significantly higher doses in patients with xerostomia, located contralaterally near the nasopharynx. Overlap with the functional PSMA-PET atlas revealed 2 clinically relevant subregions in the contralateral PG (SRSPG, 6.8 cc) and tubarial gland (SRStubarial, 12.7 cc), with doses >11.5 Gy higher in patients with xerostomia. Logistic regression models yielded high predictive performance, with maximum areas under the curve of 0.88 for SRSPG and 0.88 for SRStubarial. CONCLUSIONS: VBA revealed 2 predictive subregions-within the contralateral PG and tubarial glands-strongly associated with xerostomia at 12 months post-RT. Our findings offer a plausible explanation for the persistence of xerostomia despite PG sparing and support incorporating subregional dose metrics and tubarial gland sparing into RT planning.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Cubero L, Acosta O, Pascau J, et al. Voxel-based Analysis Identifies New Functional Subregions Predictive of Xerostomia After Head and Neck Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 41707993. doi:10.1016/j.ijrobp.2026.01.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。